Corning Jerry Pharmaceutical-B (09966) announced interim results. Shareholders' losses of 404.61 million yuan turned profit and loss year on year

According to the Zhitong Finance App, Corning Jerry Pharmaceutical-B (09966) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 271 million yuan, a year-on-year decrease of 15.09%; a loss of 404.61 million yuan during the period, compared with a profit of 21.575 million yuan in the same period last year; a loss of 0.04 yuan per share.

The Group will continue to strive to provide world-class innovative therapeutic biologics to patients around the world through our unique drug discovery and development capabilities. With our strong independent R&D capabilities and technical platform, we discover, validate and select leading drug candidates to enrich early pipelines and focus on ADCs. We will also continue to optimize manufacturing processes and technology to improve product quality and reduce costs. To maximize the commercial value of our global patent assets, we will continue to actively seek more strategic cooperation opportunities, such as joint development, joint development cooperation and external licensing.